SPG7 (Spastic Paraplegia 7) is a gene located on chromosome 16q24.3 that encodes paraplegin, a mitochondrial-inner-membrane AAA ATPase (ATPases Associated with diverse cellular Activities). Mutations in SPG7 cause a form of autosomal recessive hereditary spastic paraplegia (HSP) characterized by progressive lower limb spasticity, optic atrophy, and often cerebellar ataxia[1][2].
The gene encodes paraplegin, a 795-amino-acid protein (approximately 88 kDa) that assembles into a 19-subunit m-AAA protease complex embedded in the mitochondrial inner membrane. This complex is essential for mitochondrial protein quality control, mitochondrial dynamics, and respiratory chain assembly. The protein was first linked to neurodegeneration when Casari et al. identified pathogenic mutations in a family with complicated hereditary spastic paraplegia[1:1].
SPG7 mutations are among the most common causes of autosomal recessive HSP, accounting for approximately 5-10% of all cases. Over 60 pathogenic variants have been identified, spanning truncating mutations, missense variants, and splice site mutations[3].
The SPG7 gene spans approximately 34 kb and contains 16 exons. The gene encodes paraplegin, a mitochondrial protein with the following structural features:
Paraplegin does not function as a standalone protein — it assembles with its close homolog YME1L1 (also known as YME1L) to form the m-AAA protease complex. This complex:
Paraplegin is highly conserved across eukaryotes, with orthologs in yeast (m-AAA protease subunits mta1 and mta2) and across vertebrates. The AAA module structure places SPG7 in the AAA+ family, which includes FtsH proteases, ClpXP, and other quality control proteases that use ATP hydrolysis to fuel protein unfolding and degradation.
The primary function of the paraplegin-containing m-AAA protease complex is the ATP-dependent degradation of mitochondrial proteins[4:1]:
Paraplegin regulates mitochondrial morphology through at least two mechanisms:
Paraplegin is critical for maintaining respiratory chain complex I (NADH:ubiquinone oxidoreductase) integrity:
Paraplegin is expressed in all tissues with highest levels in brain, spinal cord, and muscle. Within the nervous system:
The canonical disease caused by SPG7 mutations is autosomal recessive hereditary spastic paraplegia type 7 (SPG7). This is a complicated HSP with both upper motor neuron features (spasticity) and multi-system involvement[3:1].
Epidemiology:
Core Clinical Features:
Upper Motor Neuron Involvement:
Optic Atrophy:
Cerebellar Ataxia:
Additional Features:
Genotype-Phenotype Correlation:
Beyond spastic paraplegia, SPG7 mutations have been associated with:
Bidirectional Chorea: Pfeffer et al. (2017) identified SPG7 mutations in patients presenting with chorea (involuntary movements in both directions), sometimes in combination with spasticity. This expands the phenotypic spectrum of SPG7 beyond pure HSP[8].
Parkinsonism: Rare reports of SPG7 patients presenting with parkinsonian features (bradykinesia, rigidity, tremor). This may reflect overlap between SPG7-related neurodegeneration and other neurodegenerative movement disorders.
Spastic Ataxia: Some patients present primarily with cerebellar ataxia without prominent spasticity, suggesting a phenotypic continuum between pure HSP and ataxia syndromes.
While SPG7 is classically associated with hereditary spastic paraplegia, several lines of evidence suggest broader relevance to neurodegeneration[9]:
Overlap with ALS: Mitochondrial dysfunction is central to ALS pathogenesis. SPG7 mutations causing mitochondrial proteostasis defects may sensitize motor neurons to ALS-relevant stressors.
Alzheimer's Disease: Studies have examined SPG7 variants in AD cohorts, with some evidence of association suggesting mitochondrial protein quality control defects may contribute to AD pathogenesis.
Primary Mitochondrial Disease: SPG7 mutations cause complex I deficiency, which is also observed in primary mitochondrial diseases. The mechanistic overlap suggests therapeutic strategies for primary mitochondrial disorders may benefit SPG7 patients.
Unfolded Protein Response: Mitochondrial proteostasis defects activate the mitochondrial unfolded protein response (mtUPR), which may be both protective and damaging depending on context[10].
The paraplegin-containing m-AAA protease degrades substrate proteins through an ATP-dependent mechanism:
Loss of paraplegin results in:
Paraplegin directly processes OPA1, the dynamin-like GTPase controlling inner membrane fusion and cristae junctions. In SPG7-deficient models:
Symptomatic treatment:
Genetic counseling: Critical for family planning. Autosomal recessive inheritance means 25% recurrence risk for carrier parents.
Gene therapy approaches:
Mitochondrial-targeted compounds:
Protein aggregation inhibitors: Given the mitochondrial proteostasis defect, compounds that enhance chaperone function (e.g., geldanamycin analogs, HSP90 inhibitors) are being explored.
Complex I activity enhancers: Small molecules that stabilize or enhance complex I assembly/function are in development.
Why motor neurons specifically? Spinal cord motor neurons are preferentially affected despite ubiquitous paraplegin expression. Is this due to their high metabolic demands, unique mitochondrial dynamics, or other cell-intrinsic factors?
Modifier genes: Why do patients with identical SPG7 genotypes have such variable phenotypes? What modifier genes or environmental factors influence severity?
Optic atrophy mechanism: How does paraplegin dysfunction specifically affect the optic nerve? Is it the same mechanism as corticospinal tract degeneration?
Therapeutic window: At what disease stage do interventions need to begin to be effective? Are there presymptomatic biomarkers?
Compound heterozygotes vs homozygous: Are there meaningful phenotypic differences between the two genotypes?
Overlap with primary mitochondrial disease: Should SPG7 be included in mitochondrial disease gene panels?
Spg7 knockout mice recapitulate key features of human SPG7:
Orthologous models show:
These models are being used for drug screening and gene therapy validation.
Casari G, De Fusco M, Ciarmatori S, et al. Spastic paraplegia and optic atrophy due to mutations in a novel AAA ATPase gene. Cell. 1998. ↩︎ ↩︎
Martinelli P, Battini C, Bose K, et al. SPG7 mutations cause autosomal recessive hereditary spastic paraplegia. Brain. 2009. ↩︎ ↩︎
Hewamadduma C, McDermott C, Kirmara B, et al. Genotype-phenotype correlations of SPG7 mutations in a large cohort of patients with hereditary spastic paraplegia. Neurology. 2018. ↩︎ ↩︎ ↩︎
Wernecke C, Eymess N, von Hoven G, et al. The mitochondrial AAA ATPase SPG7/ paraplegin promotes assembly of the m-AAA protease complex. J Mol Biol. 2007. ↩︎ ↩︎
Chan NC, Denner L, Chan CT, et al. Mitochondrial AAA proteases: functions of a growing family. FEBS Lett. 2010. ↩︎
Nanou E, Scheuring S, Nitschke R, et al. Mitochondrial cristae morphology in neurological disease. Neurobiol Dis. 2018. ↩︎
Rajakulendran S, Heckmann J, Clayden S, et al. A heterozygous mutation in the SPG7 gene with a novel phenotype. Pract Neurol. 2017. ↩︎
Pfeffer G, Pugh R, Ogilvie C, et al. SPG7 mutations are a common cause of bidirectional chorea. Mov Disord. 2017. ↩︎
Noreau A, Bouchard JP, Dupré N, et al. Association study of SPG7 mutations in neurodegenerative disease. Neurobiol Aging. 2012. ↩︎
Pellegrino MW, Nargund AM, Kirber K, et al. Mitochondrial stress and the unfolded protein response in neurodegeneration. Semin Cell Dev Biol. 2017. ↩︎